Fasinumab is a monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain. It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e.
- Mechanism
- Curator reviewed · 4 references
During embryonic development, nerve growth factor (NGF) binds to tropomyosin receptor kinase A receptor (TrkA) and the low-affinity p75 neurotrophin receptor (NTR) on developing neuronal cell surfaces, which activates signaling pathways involved in neuronal growth and survival. In adults, the primary role of NGF shifts towards influencing nociceptive signaling transduction by releasing inflammatory mediators and regulating ion channels or receptors.
Fasinumab is a human IgG1k monoclonal antibody targeted against NGF, interrupting pain signaling pathways and thus alleviating pain and improving function in patients suffering from chronic pain conditions.
- Code names
- MT-5547 · REGN475
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Fasinumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account